

**APPLICANTS:** Dobie et al.  
**SERIAL NO:** 10/714,796

**DOCKET NO:** HTS-0016US.P1 (ISIS.037CP1)

### REMARKS

Claims 1-8, 13-19, 23-28 and 44-68 are pending in the instant application. An Office Action has restricted the pending claims into the following groups:

Group I: Claims 1-8, 13-16, 23, 49-51, 59-61 and 65, drawn to an antisense oligonucleotide targeted to kinesin-like 1 encoding nucleic acid which comprises at least an 8 nucleobase portion of SEQ ID NO: 86;

Group II: Claims 1-8, 13-16, 23, 49-51, 59, 60, 62 and 66, drawn to an antisense oligonucleotide targeted to kinesin-like 1 encoding nucleic acid which comprises at least an 8 nucleobase portion of SEQ ID NO: 96;

Group III: Claims 1-8, 13-16, 23, 49-51, 59, 60, 63 and 67, drawn to an antisense oligonucleotide targeted to kinesin-like 1 encoding nucleic acid which comprises at least an 8 nucleobase portion of SEQ ID NO: 116;

Group IV: Claims 1-8, 13-16, 23, 49-51, 59, 60, 64 and 68, drawn to an antisense oligonucleotide targeted to kinesin-like 1 encoding nucleic acid which comprises at least an 8 nucleobase portion of SEQ ID NO: 122;

Group V: Claims 17-19, 24-28, 44-48 and 52-58, drawn to a method of inhibiting the expression of kinesin-like 1 via an antisense oligonucleotide targeted to a kinesin-like 1 encoding nucleic acid which comprises at least an 8 nucleobase portion of SEQ ID NO: 86;

Group VI: Claims 17-19, 24-28, 44-48 and 52-58, drawn to a method of inhibiting the expression of kinesin-like 1 via an antisense oligonucleotide targeted to a kinesin-like 1 encoding nucleic acid which comprises at least an 8 nucleobase portion of SEQ ID NO: 96;

Group VII: Claims 17-19, 24-28, 44-48 and 52-58, drawn to a method of inhibiting the expression of kinesin-like 1 via an antisense oligonucleotide targeted to a kinesin-like 1 encoding nucleic acid which comprises at least an 8 nucleobase portion of SEQ ID NO: 116; and

Group VIII: Claims 17-19, 24-28, 44-48 and 52-58, drawn to a method of inhibiting the expression of kinesin-like 1 via an antisense oligonucleotide targeted to a kinesin-like 1 encoding nucleic acid which comprises at least an 8 nucleobase portion of SEQ ID NO: 122.

Applicants elect Group IV, claims 1-8, 13-16, 23, 49-51, 59, 60, 64 and 68, without traverse. Applicants have canceled claims 61-63 and 65-67 and amended claim 1 to remove reference to non-elected SEQ ID NOs, as required by the restriction. Claims 8 and 64 also are

**APPLICANTS: Doble et al.**  
**SERIAL NO: 10/714,796**

**DOCKET NO: HTS-0016US.P1 (ISIS.037CP1)**


canceled herein. However, Applicants reserve the right to pursue the canceled subject matter in a divisional application. The Examiner has required restriction between product (Group IV) and process (Group VIII) claims. Applicants have elected product claims and withdrawn respective process claims, which depend from, and thus incorporate all limitations of, the elected product claims. As such, process claims 17-19, 24-28, 44-48 and 52-58 are subject to rejoinder upon allowance of the elected product claims.

Claim 1 is amended to incorporate the 12 to 50 nucleobase length limitation of now canceled claim 2 and to remove the limitation on inhibiting expression of kinesin-like 1. Claim 3 is amended to correct claim dependency. Claim 68 is amended for clarity. New claims 69-72 find basis in the application as originally filed, such as, for example, at pages 7-9 and 12-13 of the specification. No new matter has been added to the claims. Upon entry of this amendment, claims 1, 3-7, 13-19, 23-28, 44-60 and 68-72 will be pending.

It is believed that no fee is due with this response. However, if an additional fee is due, the Commissioner is hereby entitled to charge the fee to the Deposit Account 50-0252, referencing the above named application.

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, an early office action on the merits of the case is respectfully requested.

Respectfully submitted,

  
Jodi L. Connolly, Ph.D.  
Registration No. 54,044

Date: May 16, 2006

ISIS Pharmaceuticals, Inc.  
1896 Rutherford Rd.  
Carlsbad, CA 92008  
Telephone: (760) 603-2777  
Facsimile: (760) 603-3820